Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA. 95 (26), 15 665–15 670. https://doi.org/10.1073/pnas.95.26.15665

Article  Google Scholar 

Khunweeraphong N., Stockner T., Kuchler K. 2017. The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion. Sci. Rep. 7 (1), 13767. https://doi.org/10.1038/s41598-017-11794-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg M.F., Bikadi Z., Chan J., Liu X., Ni Z., Cai X., Ford R.C., Mao Q. 2010. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure. 18 (4), 482–493. https://doi.org/10.1016/j.str.2010.01.017

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ni Z., Bikadi Z., Rosenberg M.F., Mao Q. 2010. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Cur. Drug Metabolism. 11 (7), 603–617. https://doi.org/10.2174/138920010792927325

Article  CAS  Google Scholar 

Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., Schellens J.H. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 (8), 3458–3464.

CAS  PubMed  Google Scholar 

Natarajan K., Xie Y., Baer M.R., Ross D.D. 2012. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem. Pharm. 83 (8), 1084–1103. https://doi.org/10.1016/j.bcp.2012.01.002

Article  CAS  PubMed  Google Scholar 

Stiburkova B., Pavelcova K., Zavada J., Petru L., Simek P., Cepek P., Pavlikova M., Matsuo H., Merriman T.R., Pavelka K. 2017. Functional non-synonymous variants of ABCG2 and gout risk. Rheumatology (Oxford). 56 (11), 1982–1992. https://doi.org/10.1093/rheumatology/kex295

Article  CAS  PubMed  Google Scholar 

Ee P.L., Kamalakaran S., Tonetti D., He X., Ross D.D., Beck W.T. 2004. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 64 (4), 1247–1251. https://doi.org/10.1158/0008-5472.can-03-3583

Article  CAS  PubMed  Google Scholar 

Yasuda S., Kobayashi M., Itagaki S., Hirano T., Iseki K. 2009. Response of the ABCG2 promoter in T47D cells and BeWo cells to sex hormone treatment. Mol. Biol. Rep. 36 (7), 1889–1896. https://doi.org/10.1007/s11033-008-9395-0

Article  CAS  PubMed  Google Scholar 

Evseenko D.A., Paxton J.W., Keelan J.A. 2007. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab. Dispos. 35 (4), 595–601. https://doi.org/10.1124/dmd.106.011478

Article  CAS  PubMed  Google Scholar 

Wang H., Zhou L., Gupta A., Vethanayagam R.R., Zhang Y., Unadkat J.D., Mao Q. 2006. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Amer. J. Physiol. Endocrinol. Metabol. 290 (5), 798–807. https://doi.org/10.1152/ajpendo.00397.2005

Article  CAS  Google Scholar 

Wang H., Lee E.W., Zhou L., Leung P.C., Ross D.D., Unadkat J.D., Mao Q. 2008. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol. Pharm. 73 (3), 845–854. https://doi.org/10.1124/mol.107.041087

Article  CAS  Google Scholar 

Wu X., Zhang X., Sun L., Zhang H., Li L., Wang X., Li W., Su P., Hu J., Gao P., Zhou G. 2013. Progesterone negatively regulates BCRP in progesterone receptor-positive human breast cancer cells. Cell Physiol. Biochem. 32 (2), 344–354. https://doi.org/10.1159/000354442

Article  CAS  PubMed  Google Scholar 

Wu X., Zhang X., Zhang H., Su P., Li W., Li L., Wang Y., Liu W., Gao P., Zhou G. 2012. Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer. Cancer Sci. 103 (5), 959–967. https://doi.org/10.1111/j.1349-7006.2012.02245.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazaira G.I., Zgajnar N.R., Lotufo C.M., Daneri-Becerra C., Sivils J.C., Soto O.B., Cox M.B., Galigniana M.D. 2018. The nuclear receptor field: A historical overview and future challenges. Nucl. Receptor Res. 5, 101320. https://doi.org/10.11131/2018/101320

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi Y. 2007. Orphan nuclear receptors in drug discovery. Drug Discov. Today. 12 (11–12), 440–445. https://doi.org/10.1016/j.drudis.2007.04.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Serviddio G., Bellanti F., Vendemiale G. 2014. Oxysterols in the orchestra of liver cell metabolism. Free Radic. Biol. Med. 1, S6. https://doi.org/10.1016/j.freeradbiomed.2014.10.838

Article  Google Scholar 

Chiang J.Y.L., Ferrell J.M. 2022. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol. Cell Endocrinol. 548, 111618. https://doi.org/10.1016/j.mce.2022.111618

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krasowski M.D., Ni A., Hagey L.R., Ekins S. 2011. Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol. Cell Endocrinol. 334 (1–2), 39–48. https://doi.org/10.1016/j.mce.2010.06.016

Article  CAS  PubMed  Google Scholar 

Jin B., Wang W., Bai W., Zhang J., Wang K., Qin L. 2017. The effects of estradiol valerate and remifemin on liver lipid metabolism. Acta Histochem. 119 (6), 610–619. https://doi.org/10.1016/j.acthis.2017.06.004

Article  CAS  PubMed  Google Scholar 

Kawamoto T., Kakizak S., Yoshinari K., Negishi M. 2000. Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse CYP2B10 gene. Mol. Endocrinol. 14, 1897–1905. https://doi.org/10.1210/mend.14.11.0547

Article  CAS  PubMed  Google Scholar 

Blumberg B., Sabbagh W., Juguilon H., Bolado J., van Meter C.M., Ong E.S., Evans R.M. 1998. SXR, a novel steroid and xenobiotic sensing nuclear receptor. Genes Dev. 12 (20), 3195–3205. https://doi.org/10.1101/gad.12.20.3195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milona A., Owen B.M., Cobbold J.F., Willemsen E.C., Cox I.J., Boudjelal M., Cairns W., Schoonjans K., Taylor-Robinson S.D., Klomp L.W., Parker M.G., White R., van Mil S.W., Williamson C. 2010. Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function. Hepatology. 52 (4), 1341–1349. https://doi.org/10.1002/hep.23849

Article  CAS  PubMed  Google Scholar 

Wang S., Lai K., Moy F.J., Bhat A., Hartman H.B., Evans M.J. 2006. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology. 147 (9), 4025–4033. https://doi.org/10.1210/en.2005-1485

Article  CAS  PubMed  Google Scholar 

Hilgers A.R., Conradi R.A., Burton P.S. 1990. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharmac. Res. 7 (9), 902–910. https://doi.org/10.1023/A:1015937605100

Article  CAS  Google Scholar 

Sim W.C., Kim D.G., Lee K.J., Choi Y.J., Choi Y.J., Shin K.J., Jun D.W., Park S.J., Park H.J., Kim J., Oh W.K., Lee B.H. 2015. Cinnamamides, novel liver X receptor antagonists that inhibit ligand-induced lipogenesis and fatty liver. J. Pharmacol. Exp. Ther. 355 (3), 362–369. https://doi.org/10.1124/jpet.115.226738

Article  CAS  PubMed  Google Scholar 

Cherian M.T., Lin W., Wu J., Chen T. 2015. CINPA1 is an inhibitor of constitutive androstane receptor that does not activate pregnane X receptor. Mol. Pharmacol. 87 (5), 878–889. https://doi.org/10.1124/mol.115.097782

Article